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ABSTRACT
Introduction Current guidelines recommend an initial 
pleural aspiration in the investigation and management of 
suspected malignant pleural effusions (MPEs) with the aim 
of establishing a diagnosis, identifying non- expansile lung 
(NEL) and, at times, providing a therapeutic procedure. A 
wealth of research has been published since the guidelines 
suggesting that results and outcomes from an aspiration 
may not always provide sufficient information to guide 
management. It is important to establish the validity of 
these findings in a ‘real world’ population.
Methods A retrospective analysis was conducted of all 
patients who underwent pleural fluid (PF) sampling, in a 
single centre, over 3 years to determine the utility of the 
initial aspiration.
Results A diagnosis of MPE was confirmed in 230/998 
(23%) cases, a further 95/998 (9.5%) were presumed to 
represent MPE. Transudative biochemistry was found in 3% 
of cases of confirmed MPE. Positive PF cytology was only 
sufficient to guide management in 45/140 (32%) cases. 
Evidence of pleural thickening on CT was associated 
with both negative cytology (χ2 1df=26.27, p<0.001) and 
insufficient samples (χ2 1df=10.39, p=0.001). In NEL 
44.4% of patients did not require further procedures after 
pleurodesis compared with 72.7% of those with expansile 
lung (χ2 1df=5.49, p=0.019). In patients who required a 
combined diagnostic and therapeutic aspiration 106/113 
(93.8%) required further pleural procedures.
Conclusions An initial pleural aspiration does not 
achieve either definitive diagnosis or therapy in the 
majority of patients. A new pathway prioritising symptom 
management while reducing procedures should be 
considered.
INTRODUCTION
Pleural effusions are a common entity, and 
although around a third are due to malig-
nancy,1 there is a wide differential diag-
nosis. The British Thoracic Society (BTS) 
Pleural Disease guidelines recommend initial 
pleural aspiration,2 often of large volume to 
relieve breathlessness, before proceeding to 
further investigations and potentially defini-
tive treatments. Aspiration is recommended 
when a malignant pleural effusion (MPE) 
is suspected in order to obtain biochemical 
parameters (which may identify alternative 
diagnoses), provide cytology to confirm diag-
nosis and guide oncological treatment, and to 
identify both non- expansile lung (NEL) and 
those who experience symptomatic benefit, 
informing further pleural management 
choices.
Pleural fluid (PF) biochemistry allows the 
differentiation of transudate and exudate and 
identifies pleural inflammation. Although 
MPE is commonly considered to be exclusively 
exudative, case series have demonstrated tran-
sudates in 5% of cases.3 Biochemical param-
eters do not reliably differentiate between 
pleural infection and inflammatory MPE, 
with high lactate dehydrogenase (LDH), low 
glucose and low pH well recognised in either 
diagnosis.4
Key messages
 ► In the modern era, the role of a pleural aspiration in 
the investigation and management of a suspected 
malignant pleural effusion should be re- evaluated.
 ► It may be possible to triage some patients straight to 
a definitive procedure, rather than a pleural aspira-
tion, but further assessment of the applicability and 
utility of this approach is needed before firm conclu-
sions can be drawn.
 ► This study reviews the recently published trial ev-
idence and tests their conclusions in a real- world 
population, and suggests that a review of the current 
pleural pathway should be undertaken.
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PF cytology has a diagnostic sensitivity of around 60%2; 
however, with the expansion of personalised oncolog-
ical treatments which require specific molecular testing, 
insufficient information may be derived from a single 
cytology sample. Tsim et al5 demonstrated that testing 
was ‘incomplete’ (ie, insufficient material to permit 
molecular testing) in 47% of cytology positive effusions. 
In patients with a CT scan suggestive of malignancy, the 
OR for a malignant diagnosis with negative cytology was 
2.25, but specific malignant radiological features were 
not assessed.5
Large volume aspiration may reveal the presence of 
NEL, where insertion of an indwelling pleural catheter 
(IPC) is preferable to attempting pleurodesis as definitive 
pleural management.6 Therapeutic aspiration confirms 
symptomatic benefit from the pleural procedure. Psal-
lidas et al7 showed that 85.7% of patients experienced 
a clinically significant symptomatic benefit after fluid 
drainage but it was not possible to predict which patients 
would not experience symptomatic relief.
The current BTS pathway8 was proposed at a time 
where IPCs were considered second line treatment, and 
where oncological treatment options were not directed 
by molecular markers. As the focus of treatment has 
moved towards personalised treatment and patient- 
related outcomes, and new data on molecular diagnos-
tics and the value of biochemistry is available, the utility 
of initial pleural aspiration in the diagnostic pathway 
requires reassessment.
The aim of this study was to establish the utility of initial 
pleural aspiration in the diagnostic or management 
pathway of patients subsequently diagnosed with MPE. 
Specific areas addressed were: (1) if the presence of tran-
sudative biochemistry ruled out MPE; (2) the frequency 
with which malignant initial cytology materially altered 
management; (3) whether initial therapeutic aspiration 
reliably identifies NEL which influences management; 
(4) whether a single therapeutic aspiration prevented the 
need for further pleural procedures.
METHODS
Retrospective analysis was conducted of all inpatients and 
outpatients in our hospital where the first sample of PF 
obtained was between 1 January 2015 and 31 December 
2017. If a previous sample was recorded greater than 6 
months prior to the start of the study, the patient was still 
considered to represent a new case. Cases were identified 
through procedure records as, in our centre, all proce-
dures (except in emergencies) are associated with an 
electronic report on either the radiology or respiratory 
documentation systems.
Data were collected from electronic patient records 
(EPR) by two separate physicians and any disagreements 
checked by a third physician. The EPR included labora-
tory results, procedure reports, need for further ipsilateral 
pleural procedure, radiology, clinic letters, multidisci-
plinary team outcomes and discharge reports, which 
were reviewed to determine treatment plans. Data were 
included until patient death or censorship (1 January 
2019). Patients were excluded from specific analyses 
where information regarding requirement for further 
investigations, pleural procedures, treatment or date of 
death were unavailable. Drainage of over 200 mL fluid 
was considered to represent a therapeutic procedure.
CT reports, at the time of the aspiration, were reviewed 
to document radiological features of malignant pleural 
disease.9 It was assumed that radiological features were 
not present if no mention was made in the report. 
Reports were used, rather than independent reviews of 
each scan, with the aim of providing information relevant 
to a ‘real- world’ population.
The EPR was used to determine whether patients devel-
oped malignancy in the year after initial PF sampling 
was undertaken, to ensure cytology negative MPE were 
included. Follow- up of 12 months was considered suffi-
cient to establish a malignant diagnosis, as per previous 
publications.10
Definitions
Transudative effusions were identified using a cut- off 
PF protein <30 g/L and LDH <167 IU/L suitable to 
the normal ranges in our hospital. MPE was defined as 
either malignant cells in PF or malignant tissue in biopsy 
samples.
Patients were considered to have ‘confirmed MPE’ 
when there were malignant cells in either the PF or 
pleural biopsies. A broader definition of MPE (presumed 
MPE) was used for the NEL assessments due to the 
small number of patients with NEL, which required a 
larger sample size to draw meaningful conclusions. This 
included patients with pleural effusion in the context of 
histologically proven cancer elsewhere, excluding those 
with clear alterative causes,11 or a radiologically confident 
diagnosis of MPE.
A PF sample was considered sufficient to guide 
management when it provided enough information to 
allow treatment decisions on systemic anticancer treat-
ments to be made. Where no treatment was considered 
appropriate (eg, in the presence of poor performance 
status), positive cytology leading to the decision not to 
treat was considered sufficient. Cases where further biop-
sies beyond initial pleural aspiration were needed to 
determine precise anticancer therapy were deemed to 
be insufficient. Cases in which a concurrent biopsy was 
taken at the time of the first PF aspiration were excluded 
from the diagnostic analysis.
The presence of NEL was defined pre- hoc and scored 
using the following criteria by two respiratory physicians 
independently. ‘Probable’ and ‘proven’ non- expansile 
definitions as below were considered as NEL:
 ► Proven expansile: fully expanded lung, clear visualis-
ation of the costophrenic angle and no evidence of 
fluid or air within the pleural cavity.
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 ► No evidence of non- expansile: no evidence of trap-
ping (or air) in the pleural cavity but residual fluid.
 ► Probable non- expansile: small volume of air in the 
pleural cavity and/or evidence of visceral pleural 
thickening and pattern of fluid which would not be 
consistent with normal gravitational distribution.
 ► Proven non- expansile: clear evidence of air in the 
pleural cavity preventing, either partial of complete, 
apposition of the visceral pleural to the haemithorax.
Patient and public involvement statement
Patients and the public were not involved in the research.
RESULTS
Over the study period, 998 patients underwent PF aspira-
tion with multiple diagnoses (see appendix 1). In total, 
325/998 patients (32.6%) were diagnosed with MPE by 
any definition, and 230/325 (70.1%) of these had malig-
nant cells in PF or tissue samples. Table 1 provides details 
on the underlying malignancy.
Transudative effusions
In total, 223 patients with confirmed MPE had samples 
send for biochemical analysis of which, 7/223 (3.14% 
95% CI 0.9% to 5.4%) had biochemistry consistent with 
transudate. Of these, the median LDH was 117 IU/L 
(IQR 80–136) and protein was 25 g/L (IQR 20–28), 
two were systemically unwell, two had liver disease, one 
had congestive cardiac failure and two patients did not 
have any underlying diseases to suggest a transudative 
pathology.
Utility of the initial aspiration sample or radiology to guide 
management
In 152 patients (46.7%), cytological examination was 
requested to provide diagnostic information to guide 
management. Twelve underwent concurrent pleural 
biopsies and were excluded, leaving 140 patients. Of 
these 140 patients, 78 (55.7%) had positive cytology (71 
on first aspiration) and this information was sufficient to 
guide management in 45/71 (63.4%) of cytology posi-
tive cases. The initial aspiration was sufficient to guide 
management in 45/140 (32.1%) of the total number of 
MPE cases (see table 2 for details).
Baseline clinical (demographic) and radiological 
features were assessed to determine predictors of positive 
cytology, and sufficiency to guide management (tables 3 
and 4). Contemporaneous CT scans were available in 135 
cases of confirmed MPE. Pleural thickening and nodu-
larity were negatively associated with positive PF cytology 
on initial sampling whereas the presence of lymphangitis 
was associated with positive PF cytology.
Table 1 Type of cancer causing MPE and method of diagnosis
Type of cancer
Confirmed MPE Presumed MPE
Total
Confirmed versus 
presumed significance
Malignant 
cytology
Malignant 
pleural 
biopsy
Histological 
malignancy 
elsewhere
Clinical 
diagnosis
Breast 49 (84.5%) 5 (8.6%) 2 (3.4%) 2 (3.4%) 58 p<0.001
NSCLC 44 (55.7%) 11 (13.9%) 18 (22.8%) 6 (7.6%) 79 p=0.78
SCLC 4 (80%) 0 (0%) 1 (20%) 0 (0%) 5 p=0.65
Mesothelioma 3 (6.3%) 42 (87.5%) 1 (2.1%) 2 (4.2%) 48 p<0.001
Gynaecological 21 (75.0%) 0 (0%) 7 (25.0%) 0 (0%) 28 p=0.67
CUP 7 (41.2%) 2 (11.8%) 6 (35.3%) 2 (11.8%) 17 p=0.11
Lower GI 6 (37.5%) 0 (0%) 9 (56.3%) 1 (6.3) 16 p=0.008
Upper GI 5 (50.0%) 2 (20.0%) 3 (30.0%) 0 (0%) 10 p=1.00
Lymphoma 6 (37.5%) 3 (18.8%) 7 (43.8%) 0 (0%) 16 p=0.26
Melanoma 5 (83.3%) 0 (0%) 1 (16.7%) 0 (0%) 6 p=0.68
Pancreatic 2 (40.0%) 0 (0%) 0 (0%) 3 (60.0%) 5 p=0.15
Urological 4 (40.0%) 1 (10.0%) 5 (50.0%) 0 (0%) 10 p=0.16
Head and neck 0 (0%) 1 (20.0%) 4 (80.0%) 0 (0%) 5 p=0.03
Sarcoma 0 (0%) 0 (0%) 6 (100%) 0 (0%) 6 p<0.001
Other 6 (54.5%) 1 (9.1%) 4 (36.4%) 0 (0%) 11 p=0.74
Unclear 0 (0%) 0 (0%) 2 (40.0%) 3 (60.0%) 5 p=0.002
Total 162 (49.8%) 68 (20.9%) 76 (23.4%) 19 (5.8%) 325   
Fishers exact test used for all calculations.
CUP, cancer of unknown primary; GI, gastrointestinal; MPE, malignant pleural effusion; NSCLC, non- small cell lung cancer; SCLC, small cell 
lung cancer.
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Due to the known low sensitivity of fluid cytology in 
the diagnosis of malignant mesothelioma,12 the analysis 
was repeated excluding mesothelioma cases (n=43). 
The negative predictive value of pleural thickening for 
cytology positivity remained (χ2 1df=11.66, p=0.001).
Non-expansile lung
Radiology post initial aspiration of sufficient quality to 
identify NEL was available in 318/325 patients (97.8%). 
Probable or proven NEL was found in 64/318 (20.1%) 
patients; in 38/318 (11.9%), at least one reviewer 
reported proven NEL but both initial reviewers only 
agreed there was proven NEL in 19/318 (6%) of cases.
Therapeutic aspiration with a chest radiograph within 
the next 24 hours was conducted in 153/325 (47.1%, 
mean drainage 1114 mL SD 458). After initial aspiration 
radiograph results, pleurodesis was not attempted due 
to evidence of NEL in 7/153 (4.6%) cases. In one case, 
the lung was later shown to be expansile but was non- 
expansile in the remaining 6. The sensitivity and speci-
ficity of the initial post aspiration chest radiograph for 
the diagnosis of NEL was 24.0% (95% CI 9.4% to 45.1%) 
and 99.2% (95% CI 95.7% to 100.0%).
Of 106 patients who underwent pleurodesis, 18 radio-
graphs were classified as NEL, 1 of whom had evidence of 
NEL prior to a diagnostic thoracoscopy, but an attempt 
at pleurodesis was considered appropriate. 8/18 (44.4%) 
patients with NEL did not require any further pleural 
procedures at 3 months (or until death) compared with 
64/88 (72.7%) in the patients with no evidence of NEL 
(χ2 1df=5.49, p=0.019). When 10 patients in the probable 
NEL group were compared with those without evidence 
of NEL, there was still a significantly higher requirement 
for subsequent procedures (χ2 1df=4.53, p=0.033).
Single therapeutic aspiration only
In total, 7/113 (6.2%) patients who underwent a 
combined diagnostic and therapeutic procedure did 
not require any further pleural interventions for fluid 
control. Of patients who only required one aspiration, 
4/7 (57.1%) died within 30 days compared with 5/106 
(4.7%) of those who required more than one procedure 
(χ2 1df=24.62, p<0.0001).
DISCUSSION
The currently used pathway for investigation of potential 
MPE has been unchanged for over 15 years, despite new 
evidence on cytological accuracy, requirement for molec-
ular markers and no modern re- assessment of the utility 
of biochemical results. Pleural aspiration as an initial diag-
nostic step is promoted based on being less invasive than 
pleural biopsy techniques, allowing diagnosis of NEL and 
providing important information including ‘diagnostic’ 
cytology and the presence of transudate. In this study, 
we adopted a pragmatic approach to assess if the current 
BTS pathway remains relevant to modern practice and 
to ensure that recently published study results are appli-
cable to real- world practice.
In the present study, 3% of those with confirmed MPE 
had transudative biochemistry, which is consistent with 
previously published data.3 It is widely recognised that 
pH and glucose may be low in both MPE and many other 
pathologies.4 These data suggest that biochemical results 
alone are insufficient to completely exclude MPE as a 
cause of an undiagnosed effusion.
Sensitivity of PF for cytological diagnosis is between 
46% and 67% for patients with MPE,1 13 14 although a 
recent study showed that it was not possible to identify all 
the ‘necessary predictive markers’ in 47% of cases.5 The 
aim of the present study was to use a pragmatic approach 
to determine the utility of the information gleaned from 
PF cytology, that is, whether the information was suffi-
cient to guide ongoing management. A positive manage-
ment decision covered a spectrum of outcomes from 
palliation at one end to initiation of mutation driven 
oncological therapies at the other. Despite this broad 
Table 2 Details of treatment decisions
Treatment decision Patients
Diagnostic only—not fit for SACT 7 (15.6%)
SACT options not suitable for patient 12 (26.7%)
Immunotherapy or hormonal therapy initiated 9 (20.0%)
Chemotherapy initiated 13 (28.9%)
SACT altered in response to results 1 (2.2%)
Patient refused treatment 3 (6.6%)
SACT, systemic anti cancer treatment.
Table 3 Positive cytology related to gender and CT scan features
Cytology positive in initial pleural fluid sample
SignificanceYes No
Male gender 27/71 (38%) 49/69 (71%) χ2 1df=15.34, p<0.001
Pleural thickening 29/68 (43%) 57/67 (85%) χ2 1df=26.27, p<0.001
Pleural nodularity 22/68 (32%) 39/67 (58%) χ2 1df=9.11, p=0.003
Lymphangitis 12/68 (18%) 2/67 (3%) χ2 1df=7.81, p=0.005
Pericardial effusion 3/68 (4%) 6/67 (9%) χ2 1df=1.12, p=0.290
Thoracic lymphadenopathy 37/68 (54%) 30/67 (45%) χ2 1df=1.25, p=0.263
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range of acceptable outcomes, an initial pleural aspira-
tion provided sufficient information to guide manage-
ment in only 63% of patients who had initially positive 
PF cytology, and in 32% of cases of MPE as a whole. If the 
analysis also included patients with ‘presumed’ MPE, the 
success rate is likely to be even lower.
The majority of patients with MPE experience fluid 
recurrence and require definitive management of the 
pleural space. A suggested role of a large volume aspi-
ration is to diagnose NEL, and thus to prevent patients 
undergoing pleurodesis which is likely to be unsuc-
cessful. A recently published study showed that NEL is 
present in between 17% and 34% of MPE, but is difficult 
to diagnose on chest radiograph.15 In view of this finding, 
patients were categorised into ‘proven’ and ‘probable’ 
NEL to establish the incidence of both types of NEL, the 
ability to detect NEL after one aspiration and whether 
NEL affects pleurodesis success. The prevalence ranged 
from 6% to 20%, but the sensitivity of the post procedure 
chest radiograph for detecting NEL was only 24%. In 
patients who underwent pleurodesis there was a signifi-
cantly higher requirement for further procedures, indi-
cating treatment failure, in those diagnosed with NEL. 
This finding makes sense, as there is a lack of pleural 
apposition in NEL, but importantly, this difference was 
maintained even when those with probable NEL alone 
were analysed. This suggests that any suspicion of NEL 
on chest radiograph is likely to be associated with pleu-
rodesis failure, but this is often not evident until after the 
first post procedure radiograph.
Out of a cohort of 113 patients who required both an 
initial diagnostic and therapeutic intervention only 7 
(6%) patients required a single aspiration, and only 3 of 
these patients survived over 30 days after the procedure.
There is a wealth of information which may now help 
to inform a ‘new pleural pathway’. Our study confirms 
the findings from Tsim et al that CT evidence of malig-
nancy was associated with negative cytology5; specifically 
the present study demonstrated that pleural thickening 
and nodularity are highly associated with negative PF 
cytology. Importantly, the significance of pleural thick-
ening was maintained even when patients with mesothe-
lioma (which could be a confounder considering the 
high rates of thickening and low cytology positivity) were 
excluded.
The CT finding of lymphangitis was associated with 
positive PF cytology—this could represent more advanced 
malignancy or relate to the manner in which tumours 
metastasise. Further studies with robust criteria to ensure 
that radiology reports are standardised are needed to 
validate these findings. If such features are consistently 
predictive, it may be possible to stratify patients to 
different initial diagnostic techniques according to the 
likelihood of obtaining sufficient cytology on the basis of 
the initial CT findings.
Another compelling argument for changing the current 
pathway is the burden of symptoms for the patients. 
Studies have shown that symptomatic benefits after a 
therapeutic aspiration are transient, and sometimes only 
last a matter of days.16 There is evidence to show that 
diagnostic uncertainty is detrimental to the patient’s well- 
being17 and this, in combination with distressing symp-
toms, may be a consequence of the current prolonged 
pathway. Tsim et al showed that the median time from first 
outpatient appointment (or emergency admission) to 
diagnosis was 26 days, which may not necessarily include 
the time to definitive management of the pleural space 
and therefore relief of symptoms.5 Further qualitative 
work is needed to map the patient experience of MPE to 
ensure that any revised pathway takes this into account.
A number of alternative diagnostic pathways have been 
suggested such as a ‘straight to local anaesthetic thoraco-
scopy’ approach for patients with a higher risk of meso-
thelioma (asbestos exposure and a suggestive CT scan).5 
Non- invasive ultrasound methods such as speckle tracking 
and M mode ultrasound have a reported sensitivity of 
71% and 50%, respectively, with a specificity of 85%18 
in identifying NEL and could be used to triage patients 
to IPC or pleurodesis. The PRE- EDIT (Elastase- Directed 
Intrapleural Catheter or Talc Pleurodesis) study trialled 
use of manometry to detect NEL and triage to pleurod-
esis or IPC, depending on pleural pressures.19 Bhatnagar 
et al20 proved that instilling talc via an IPC increases the 
spontaneous pleurodesis rate in MPE treated with IPC (to 
around 50%). Despite all the above advances, a rational 
pathway combining all relevant information has yet to be 
produced.
On this basis of our data, it may be appropriate to 
adopt an approach which moves straight to a definitive 
procedure in a subset of cases. In a diagnostic setting, 
Table 4 Actionable cytology related to gender and CT scan features
Sample sufficient to guide management
SignificanceYes No
Male gender 20/45 (44%) 56/95 (59%) χ2 1df=2.58, p=0.108
Pleural thickening 19/43 (44%) 68/92 (74%) χ2 1df=10.39, p=0.001
Pleural nodularity 13/43 (30%) 49/92 (53%) χ2 1df=5.70, p=0.017
Lymphangitis 9/43 (21%) 5/92 (5%) χ2 1df=7.57, p=0.006
Pericardial effusion 4/43 (9%) 5/92 (5%) χ2 1df=0.74, p=0.401
Thoracic lymphadenopathy 27/43 (63%) 40/92 (43%) χ2 1df=4.37, p=0.037
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this could be straight to local anaesthetic thoracoscopy 
or image guided biopsy, especially in cases where it is 
well recognised that the cytological yield is low, such as in 
suspected mesothelioma. Likewise, in cases where there 
is a high suspicion of MPE and patient preference is for 
an IPC, it may be appropriate to perform IPC insertion as 
a first line management option. Removal of IPCs shortly 
after insertion is relatively uncomplicated due to the lack 
of adhesion formation and is therefore easily reversible if 
a non- MPE diagnosis is achieved, or if IPC treatment was 
not tolerated and outpatient pleurodesis can be under-
taken through the IPC.
Further work is needed before these strategies are 
adopted into clinical practice. Risk stratification would 
need to be validated to establish which patients would 
benefit from an initial pleural biopsy, the relative compli-
cations of an IPC versus an aspiration would need to be 
established and importantly qualitative work would need 
to be undertaken to ensure acceptability to patients. 
Even if an alternative pathway was found to be benefi-
cial, it would not necessarily be feasible to introduce on a 
national scale, due to differences in availability of proce-
dures between hospitals. For centres with access to some, 
or all, of these procedures, clear evidence on the risks 
and benefits of a more tailored approach is critical to 
shared decision making with patients.
This study has significant limitations, mainly the retro-
spective nature which means that relevant, available 
data could have been missed. The diagnosis of a transu-
dative effusion was made solely on the PF biochemistry, 
which is less reliable than the use of Light’s criteria, but 
the findings from this cohort are consistent with other 
published literature. The decision regarding whether the 
PF cytology was sufficient to guide treatment was made 
on retrospective data, and there could have been varia-
tions in practice between clinicians. The radiology was 
not performed at the time of the aspiration so there may 
have been changes to the radiological features described 
when the aspiration was undertaken. Despite this, the 
real- world cohort is concordant with published literature 
within trial populations, which provides credibility to 
previous findings.
Further important work includes review of radiology 
for all patients who underwent aspiration to assess what 
proportion of CT scans reported a suspicion of malig-
nancy which was later disproved. In a revised pathway 
with a ‘straight to IPC’ option, this would help to iden-
tify the number of patients who may have unnecessary 
IPC insertion, although many of these patients would still 
have pleural biopsies undertaken later on as part of the 
current pathway if negative PF cytology was obtained.
In conclusion, the current BTS pathway which suggests 
initial pleural aspiration for diagnostic and therapeutic 
purposes does not often achieve either definitive diag-
nosis or therapy and our study suggests a review of the 
current approach would be beneficial. Further research 
is required with a focus on patient reported outcomes, to 
provide a novel pathway which prioritises symptoms and 
minimises procedures in this patient population where 
the focus is on improving, rather than sustaining, life, 
but this must always take into account the ability of the 
pathway to be performed in a range of centres. Recent 
advances in cancer care and information on optimal 
pleural disease management may provide the oppor-
tunity to make a significant difference to the lives of 
patients with MPE.
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